Comparing two blood thinners for staph bloodstream infections
Treatments studied
Part of Heart & circulation, Infections clinical trials.
This study compares two types of blood thinners (dabigatran vs. a common Xa inhibitor like apixaban) in people with a staph infection in their blood. The goal is to see which is safer and works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking or about to start a blood thinner like apixaban, edoxaban, or rivaroxaban for a reason such as atrial fibrillation (irregular heartbeat), a blood clot in your leg or lung, or after hip or knee replacement surgery, with at least 30 days of treatment left.
- You have a staph infection in your bloodstream.
- You have not used dabigatran in the past month and are not allergic to it.
- You are not taking certain other medications (like amiodarone, ketoconazole, rifampin, verapamil, clopidogrel, prasugrel, or ticagrelor).
- Your kidney function is adequate (eGFR at least 30 mL/min). If it is temporarily low, you may be able to join if it improves within 5 days.
- You are not pregnant, do not have active bleeding, do not need major heart, brain, or spine surgery in the next 3 days, and do not have a mechanical heart valve, a clot in the heart's left ventricle, or a condition called antiphospholipid antibody syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching from aspirin to clopidogrel better protects your heart and blood vessels during recovery from a serious staph infection in the blood. You may be eligible if you currently take aspirin for heart or stroke prevention.
This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This study compares two types of blood-thinning medicines to see which one is better at preventing another stroke in people who had a stroke without a clear cause. It may help if you had a stroke recently and have certain heart-related risk factors.
This trial is testing two blood thinners (edoxaban and apixaban) to see how they compare in preventing new brain spots on MRI after a stroke in people with atrial fibrillation. It may help you and your doctor choose the safer option.
This trial tests whether adding clopidogrel, a blood-thinning medicine usually used for heart conditions, can improve outcomes for patients with a serious staph infection in the blood, called Staphylococcus aureus bacteremia. Clopidogrel may help reduce the damage caused by the bacteria.
Hear when a new Staphylococcus Aureus Endocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.